Company Overview and News
Fortunately, there a certain sectors of the Chinese economy that will actually grow during the bust.
Almost one year ago, I wrote about the rumored merger between InBev (NYSE:BUD) and SABMiller. And here we find ourselves again, with InBev purposing a $104 billion bid merger with SABMiller, a bid SABMiller is rejecting for the time being.
Analysts say he sees property as a profit engine for his state-owned company, and that China’s largest housebuilder would provide good synergy for its real estate businesses
In this Wednesday, Nov. 11, 2015, photo, a worker prepares cooked ducks for sale at a Wal-Mart in Shenzhen, in southern China\'s Guangdong province. If Arkansas-based Wal-Mart wants to win over foreign consumers, it has to shed some of its American ways, and cater to very different customs and conventions. China is the ultimate prize. (AP Photo/Ng Han Guan)
SHENZHEN, China (AP) " Zhong Guoyan sifted through piles of fish at a Wal-Mart in Shenzhen, one of China's largest cities. She studied the fins, to make sure they were bright red and firm. She peered at the eyeballs " were they bulging?
Copies of the Annual Report and Financial Statements for the year ended 31 December 2015 have been submitted electronically to the National Storage Mechanism and will shortly be available for inspection at http://www.morningstar.co.uk/uk/nsm.
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...
2018-05-21 - Asif
Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...
2018-05-21 - Asif
Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...